SUPPORTING INFORMATION to the article

From Batch to Continuous Flow Bioprocessing: Use of an Immobilized γ-Glutamyl Transferase from *B. subtilis* for the Synthesis of Biologically Active Peptide Derivatives

Marina S. Robescu^a, Francesca Annunziata^b, Valeria Somma^c, Cinzia Calvio^d, Carlo F. Morelli^c, Giovanna Speranza^c, Lucia Tamborini^b, Daniela Ubiali^a, Andrea Pinto^e*, Teodora Bavaro^a*

^a Department of Drug Sciences, University of Pavia, viale Taramelli 12, Pavia, Italy

^b Department of Pharmaceutical Sciences, University of Milano, via Mangiagalli 25, Milano, Italy

^c Department of Chemistry, University of Milano, via Golgi 19, Milano, Italy

^d Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, via Ferrata 1, Pavia, Italy

^e Department of Food, Environmental and Nutritional Sciences, University of Milano, via Celoria 2, Milano, Italy

*Corresponding authors: teodora.bavaro@unipv.it

andrea.pinto@unimi.it

Table of contents

Supplementary Figures	
Figure S1. Shelf-life of <i>Bs</i> GGT-GLX-AG under storage (4 °C)	1
Figure S2. Preparative synthesis of γ -E-methionine (1) at the 3 hours endpoint	2
Figure S3. Preparative synthesis of γ -E-(S)-allyl-cysteine (2) at the 3 hours endpoint	2
Figure S4. Preparative synthesis of γ -E-taurine (3) at the 24 hours endpoint	3
Figure S5. Preparative synthesis of ophthalmic acid (4) at the 3 hours endpoint	3
Supplementary Tables	
Table S1. In-flow synthesis of γ -E-(S)-allyl-Cys (2): study of reaction parameters	4



Figure S1. Shelf-life of *Bs*GGT-GLX-AG under storage (4 °C).



Figure S2. Preparative synthesis of γ -E-methionine (1) at the 3 hours endpoint. $1 = \gamma$ -E₃-Gln; $2 = \gamma$ -E₂-Gln; $3 = \gamma$ -E-Gln; 5 = Gln; 7= serine (internal standard); 11= excess of Sanger's reagent; 12 = glutamic acid; 13= ammonia; 14= derivatization artifact; 17= γ -E-methionine (1); 18 & 19= derivatization artifacts; 20= methionine.



Figure S3. Preparative synthesis of γ -E-(*S*)-allyl-cysteine (**2**) at the 3 hours endpoint. 2= γ -E₃-Gln; 3= γ -E₂-Gln; 4= γ -E-Gln; 6= Gln; 8= serine (internal standard); 12= excess of Sanger's reagent; 13= glutamic acid; 14= ammonia; 15= derivatization artifact; 17= γ -E₂-(S)-allyl-cysteine; 19= γ -E-(*S*)-allyl-cysteine (**2**) (overlaps with the peak of a derivatization artifact; the conversion of **2** was corrected taking into account the peak area of the derivatization artifact); 22= (*S*)-allyl-cysteine.



Figure S4. Preparative synthesis of γ -E-taurine (**3**) at the 24 hours endpoint. 3= taurine; 4= γ -E-Gln; 5= γ -E-taurine (**4**); 7= Gln; 9= serine (internal standard); 11= excess of Sanger's reagent; 12= glutamic acid; 13= ammonia; 14 and 15= derivatization artifacts.



Figure S5. Preparative synthesis of ophthalmic acid (4) at the 3 hours endpoint. $2 = \gamma - E_3 - Gln$; $3 = \gamma - E_2 - Gln$; $4 = \gamma - E - Gln$; $6 = putative \gamma - E_3 - AbuGly$; 7 = Gln; $8 = putative \gamma - E_2 - AbuGly$; 9 = serine (internal standard); $11 = ophthalmic acid (\gamma - E - AbuGly, 3)$; 12 = excess of Sanger's reagent; 13 = glutamic acid; 14 = ammonia; 15 = derivatization artifact; 16 = AbuGly; 18 = derivatization artifact.

Entry	[L-Gln] ^a	[SAC] ^a	Res. time	T (°C)	P (har)	Gln	γ-E-SAC (2)	Glu (%)	γ-EE-SAC	γ-EEE-SAC	γ-E-Gln	γ-EE-Gln	γ-EEE-Gln	γ-E-Glu
Batch 1	(IIIVI) 100	100	(1111)	25	(Dar)	(70)	(%)	(%)	(%)	(%)	(%) 5 2	(%)	(%)	(%)
Datch 1	100	200	180	25	atin	0.4	30.2	9.1 12.7	12.0	0.7	3.5	2.5	1.0	2.4
Batch 2	100	300	180	25	atm	4.2	48.4	12.7	8.9	2.2	2.8	0.6	0	1.6
1	100	100	15	25	atm	1.4	18.5	58.0	4.6	0	1.4	0	0	5.0
2	100	100	30	25	atm	0	11.0	82.2	0	0	0	0	0	3.4
3	100	100	60	25	atm	0	4.6	87.4	0	0	2.2	0	0	1.8
4	100	100	30	30	atm	0	9.5	78.9	0	0	2.4	0	0	3.4
5	100	100	15	30	atm	2.4	28.1	32.8	6.9	2.3	1.8	1.0	0	4.8
6	100	100	5	30	atm	10.5	29.2	18.4	8.3	1.5	5.4	1.8	0	2.4
7	100	100	5	25	atm	15.1	30.5	11.1	6.9	1.7	7.5	1.8	0	2.1
8	100	100	2	25	atm	38.1	19.8	4.5	3.6	0.9	11.2	1.8	0	0
9	100	100	5	37	atm	11.2	26.8	21.4	7.6	1.4	5.3	1.7	0	2.7
10	100	100	15	37	atm	1.7	21.3	47.4	4.6	1.7	0.8	1.5	0	4.7
11	100	100	5	25	8	8.7	32.5	24.1	8.8	0	5.6	0	0	3.0
12	200	200	5	25	atm	22.1	22.5	10.3	5.4	1.6	9.9	2.4	0	1.4
13	200	200	15	25	atm	3.6	30.4	31.3	8.4	0	3.4	1.2	0.5	1.5
14	100	50	5	25	atm	13.2	15.2	18.8	5.5	0	9.4	3.9	1.2	3.2
15	150	50	5	25	atm	22	9.9	8.3	3.3	0.7	14.1	5.1	1.2	1.4
16	200	200	5	25	8	1	24.2	15.2	7.2	0	9.1	3.0	0	2.5
17	200	200	5	25	16	17.6	26.2	12.4	7.7	0	8.3	2.7	0	1.9
18	400	200	5	25	8	27	15.3	6.5	4.1	0	13.3	3.8	0.8	0.8
19	400	200	5	25	atm	23.7	17.3	8.4	4.2	0	12.2	3.8	0.9	1.4
20	100	200	5	25	atm	8.3	35.0	17.2	9.1	1.0	4.5	1.4	0.3	2.0
21	100	200	15	25	atm	1.9	35.0	33.6	8.0	0.9	1.4	0.4	0	3.4
22	100	200	5	25	8	6.2	32.9	20.5	8.2	1.1	6.1	1.1	0	2.4
23	100	300	5	25	atm	12.9	45.2	11.6	6.5	1.1	4.7	0.8	0	1.1
24	100	300	15	25	atm	1.7	40.6	31.6	7.4	1.4	1.2	0	0	2.3
25	100	300	5	25	8	9.6	38.0	15.3	8.5	1.2	4.6	1.3	0	1.6

Table S1. In-flow synthesis of γ -E-(*S*)-allyl-Cys (**2**): study of reaction parameters.

^a [L-Gln] and [SAC] resulting after mixing in the T-piece.